| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
TFAP selectively targets the cyclooxygenase-1 (COX-1) enzyme by binding to its active site. It exhibits high selectivity for COX-1 over COX-2, with an IC50 of 0.8 µM against COX-1 and an IC50 greater than 200 µM against COX-2. By selectively inhibiting COX-1, TFAP interferes with the synthesis of prostaglandins derived from arachidonic acid.
|
|---|---|
| ln Vitro |
TFAP exhibits selectivity as an inhibitor of cyclooxygenase-1 (COX-1) with an IC50 of 0.8 μM and a high IC50 against COX-2, exceeding 200 μM.
In vitro, TFAP is a potent and selective COX-1 inhibitor with an IC50 of 0.8 µM, while its IC50 against COX-2 is over 200 µM. This high selectivity distinguishes TFAP from non-selective COX inhibitors. The compound is cell-permeable and is used in biochemical assays to study COX-1 inhibition and prostaglandin synthesis. |
| ln Vivo |
In vivo, TFAP displays analgesic properties in mice and rats without long-term cytotoxic effects. It exhibits analgesic effects at an oral dose as low as 10 mg/kg in rats and causes little gastric damage even at an oral dose of 300 mg/kg. Unlike COX-2-inhibiting analgesics such as aspirin, TFAP does not cause gastric damage in rats in vivo.
|
| Enzyme Assay |
The in vitro enzyme assay for TFAP measures its inhibition of COX-1 and COX-2 activity. The enzyme is incubated with arachidonic acid substrate and varying concentrations of TFAP, and the production of prostaglandins is quantified by immunoassay or chromatographic methods. The IC50 values are calculated from dose-response curves, with TFAP showing an IC50 of 0.8 µM for COX-1 and >200 µM for COX-2.
|
| Cell Assay |
In vitro cell-based assays for TFAP use cell lines such as macrophages or other COX-expressing cells. Cells are treated with serial dilutions of TFAP, and prostaglandin E2 (PGE2) production is measured by ELISA as a readout of COX activity. Cell viability is assessed using MTT or other assays to evaluate cytotoxicity. The compound's selectivity for COX-1 over COX-2 is confirmed by comparing IC50 values in these assays.
|
| Animal Protocol |
In vivo animal models for TFAP include mouse and rat models of pain and inflammation. The compound is administered orally at doses ranging from 10 to 300 mg/kg. Analgesic efficacy is evaluated using standard pain models such as the writhing test or hot plate test. Gastric damage is assessed by examining the stomach mucosa for lesions after oral administration.
|
| ADME/Pharmacokinetics |
TFAP is orally bioavailable and is administered in vivo via oral gavage. The compound is soluble in DMSO and ethanol, with limited aqueous solubility. It is metabolized and excreted in urine, with urine turning a red-purple color after administration. Pharmacokinetic studies have identified urine metabolites of TFAP.
|
| Toxicity/Toxicokinetics |
TFAP has a favorable safety profile in preclinical studies. It exhibits no long-term cytotoxic effects in mice at doses up to 300 mg/kg administered orally for 14 days. Unlike many NSAIDs, TFAP does not cause gastric damage in rats even at high oral doses (300 mg/kg). The compound is not intended for human use and is for research purposes only.
|
| References | |
| Additional Infomation |
COX-1 inhibitors
TFAP is a research compound and is not approved for clinical use. It is available from multiple chemical suppliers for research purposes only. The compound was first reported by Kakuta et al. in 2008 as a potent COX-1-selective inhibitor. Its structure is N-(5-aminopyridin-2-yl)-4-(trifluoromethyl)benzamide with a molecular weight of 281.23 g/mol and formula C13H10F3N3O. The compound is stored as a powder at -20°C for up to 3 years. |
| Molecular Formula |
C13H10F3N3O
|
|---|---|
| Molecular Weight |
281.2332
|
| Exact Mass |
281.078
|
| CAS # |
1011244-68-0
|
| Related CAS # |
1011244-68-0;
|
| PubChem CID |
24752865
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.589
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
340
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=CC=C1C(=O)NC2=NC=C(C=C2)N)C(F)(F)F
|
| InChi Key |
BTCFFMPDIBWZLF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H10F3N3O/c14-13(15,16)9-3-1-8(2-4-9)12(20)19-11-6-5-10(17)7-18-11/h1-7H,17H2,(H,18,19,20)
|
| Chemical Name |
N-(5-aminopyridin-2-yl)-4-(trifluoromethyl)benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 155 mg/mL (~551.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.58 mg/mL (9.17 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.58 mg/mL (9.17 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: 2.58 mg/mL (9.17 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5558 mL | 17.7790 mL | 35.5581 mL | |
| 5 mM | 0.7112 mL | 3.5558 mL | 7.1116 mL | |
| 10 mM | 0.3556 mL | 1.7779 mL | 3.5558 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA